Community/Retail

Chris Van Norman discusses how technology, automation, and dedicated frontline teams keep the company's supply chain resilient and patient-focused.

Oncology pharmacists step into precision care—tracking mRNA vaccines, frailty-guided supportive therapy, NGS actionability, and new thoracic targets.

Two pharmacy owners share real-world strategies for integrating artificial intelligence (AI) and automation to boost efficiency, expand clinical capacity, and elevate patient care.

Nancy Lyons, vice president and chief pharmacy officer at Health Mart, explains how McKesson Amplify and pharmacist-told patient care stories are driving advocacy wins for independent pharmacies at the state and federal levels.

New GI cancer data highlight emerging targeted therapies, ctDNA-guided surveillance, and pharmacist-led workflows to boost outcomes.

The Moderna mRNA influenza vaccine won the FDA panel vote, but ACIP turmoil and a legal fight could threaten its fall 2026 rollout.

As multimodal analgesia and novel therapies such as suzetrigine expand treatment options, nonopioid approaches are playing an increasingly important role in acute pain management while helping reduce reliance on opioids.

Pharmacy technicians are uniquely positioned to shape patient experience.

New breast cancer trial insights reshape metastatic care: Sacituzumab benefits broadly, oral SERDs lag, and denosumab every 12 weeks suffices.

From artificial intelligence (AI)-driven dispensing to specialty service diversification, Jaime Montuoro, PharmD, previews the education lineup at McKesson ideaShare 2026.

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.

McKesson ideaShare 2026 brings independent pharmacy's premier gathering to Denver, June 18-21, with Pharmacy Times on-site for exclusive interviews and coverage.

Cheeley maps out the resources—courses, certifications, communities, and a retail pharmacy call to action—that can take any pharmacist deeper into lipid management.

With this approval, Capvaxive is the only PCV specifically indicated and studied in the US for use in this patient population.

FDA approval of the first generic version of baloxavir marboxil brings an affordable single-dose flu treatment, boosting access for the 2026-27 influenza season.

FDA approval expands Breztri Aerosphere from COPD to asthma, offering single-inhaler triple therapy for adults and pediatric patients 12+.

A new Lancet study provides the first plausible evidence that a national package of food labeling, marketing restrictions, and school food policies can reduce excess weight among young children.

The FDA approved Rextovy, a 4-mg OTC naloxone nasal spray, expanding public access to a lifesaving opioid overdose reversal medication and increasing the availability of nonprescription treatment options.

The indication is for complicated urinary tract infections (UTIs) caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options.

Chiadi Ndumele, MD, explains why the new American Heart Association (AHA)/American College of Cardiology (ACC) guideline addresses cardiovascular-kidney-metabolic (CKM) disease as one interconnected syndrome.

Fátima Rodriguez, MD, explains how the new cardiovascular-kidney-metabolic (CKM) syndrome guideline addresses health equity, risk prediction, and the pharmacist's role in care.

The findings add to a growing body of evidence supporting metformin's role as a preventive strategy against postacute sequelae of COVID-19.

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

When pharmacists and clinical decision support software work in tandem, the result is a powerful safety net that catches medication errors before they reach patients.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

Proactive, multidisciplinary strategies for managing drug shortages.

Pharmacists are increasingly positioned to answer questions and address patient interests as peptide therapies expand rapidly across clinical settings.

Cheeley takes listeners inside her clinical decision-making process—from statin intolerance to PCSK9 inhibitors to omega-3s—and explains why patient buy-in is as important as the prescription itself.